Enspryng lowered relapse severity in patients with neuromyelitis optica spectrum disorder, according to data from the double-masked periods of the SAkura phase 3 studies presented at the MSVirtual2020 meeting.
According to a Genentech press release, a post hoc analysis found the risk for severe relapse was reduced by 79% in the group treated with Enspryng (satralizumab-mwge, Genentech) compared with the group treated with placebo.
In a separate pooled analysis of the combined double-masked period and open-label extension, satralizumab reduced relapse risk by 51% compared with those originally
Uncategorized